AnaCardio
PHARMA [...]
Gesynta Pharma
In 2020, Gesynta raised SEK 190 million in one of the year’s largest private biotech investments in the Nordic region. Now the company is one step closer to a new drug for systemic sclerosis. The future promises several innovative treatments for a number of inflammatory diseases, including cardiovascular disease and cancer.
Sprint Bioscience/Pelago
Top research is based on teamwork, with success derived from continually querying results. Pär Nordlund likens the work of a research director to the job of forming a talented corporate team.
Modus Therapeutics
Many years’ research has led Mats Wahlgren to a possible first drug treatment for acute manifestations of sickle cell anemia - a genetic condition that affects millions of people.
Oncopeptides
Oncopeptides has a new drug candidate for the treatment of a form of cancer of the blood, multiple myeloma, under development. KI Innovations played a key role in getting the project underway.
BioArctic
BioArctic is getting closer to producing a drug that substantially limits the development of Alzheimer’s.
Aprea Therapeutics
Aprea Therapeutics AB is working on the development of a new p53-based treatment for cancer. Klas Wiman is one of the company’s founders, and he draws a clear distinction between the roles of researcher and entrepreneur.
Cellaviva/Nextcell Pharma
Biobank Cellaviva offers parents-to-be the chance to store stem cells from umbilical cord blood and tissue at birth. Experiences from stem cell management have now led to the development of one of Sweden’s first cell therapy drug treatments.
Curosurf
The Curosurf story is a tale of success. To date, the drug has saved the lives of around one million premature babies worldwide. And the story is far from over. Despite being 73, Tore Curstedt returns to the lab every day - the lab where he has developed a new variant of a drug that is set to help many more babies in the future.
